Annemarieke de Jonghe1, Barbara C van Munster2, J Carel Goslings2, Peter Kloen2, Carolien van Rees2, Reinder Wolvius2, Romuald van Velde2, Marcel Levi2, Rob J de Haan2, Sophia E de Rooij2. 1. Department of Internal Medicine, Geriatrics Section (de Jonghe, van Munster, de Rooij), Department of Surgery, Trauma Unit (Goslings), Department of Orthopedic Surgery (Kloen), Department of Internal Medicine (Levi) and Clinical Research Unit (de Haan), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Geriatrics (van Munster), Gelre Hospitals, Apeldoorn, The Netherlands; Department of Geriatrics (van Rees), Department of Orthopaedic Surgery (Wolvius) and Department of Surgery (van Velde), Tergooi Hospitals, Hilversum, The Netherlands. a.dejonghe@amc.uva.nl. 2. Department of Internal Medicine, Geriatrics Section (de Jonghe, van Munster, de Rooij), Department of Surgery, Trauma Unit (Goslings), Department of Orthopedic Surgery (Kloen), Department of Internal Medicine (Levi) and Clinical Research Unit (de Haan), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Geriatrics (van Munster), Gelre Hospitals, Apeldoorn, The Netherlands; Department of Geriatrics (van Rees), Department of Orthopaedic Surgery (Wolvius) and Department of Surgery (van Velde), Tergooi Hospitals, Hilversum, The Netherlands.
Abstract
BACKGROUND: Disturbance of the sleep-wake cycle is a characteristic of delirium. In addition, changes in melatonin rhythm influence the circadian rhythm and are associated with delirium. We compared the effect of melatonin and placebo on the incidence and duration of delirium. METHODS: We performed this multicentre, double-blind, randomized controlled trial between November 2008 and May 2012 in 1 academic and 2 nonacademic hospitals. Patients aged 65 years or older who were scheduled for acute hip surgery were eligible for inclusion. Patients received melatonin 3 mg or placebo in the evening for 5 consecutive days, starting within 24 hours after admission. The primary outcome was incidence of delirium within 8 days of admission. We also monitored the duration of delirium. RESULTS:A total of 452 patients were randomly assigned to the 2 study groups. We subsequently excluded 74 patients for whom the primary end point could not be measured or who had delirium before the second day of the study. After these postrandomization exclusions, data for 378 patients were included in the main analysis. The overall mean age was 84 years, 238 (63.0%) of the patients lived at home before admission, and 210 (55.6%) had cognitive impairment. We observed no effect of melatonin on the incidence of delirium: 55/186 (29.6%) in the melatonin group v. 49/192 (25.5%) in the placebo group; difference 4.1 (95% confidence interval -0.05 to 13.1) percentage points. There were no between-group differences in mortality or in cognitive or functional outcomes at 3-month follow-up. INTERPRETATION: In this older population with hip fracture, treatment with melatonin did not reduce the incidence of delirium. TRIAL REGISTRATION: Netherlands Trial Registry, NTR1576: MAPLE (Melatonin Against PLacebo in Elderly patients) study; www.trialregister.nl/trialreg/admin/rctview.asp?TC=1576.
RCT Entities:
BACKGROUND: Disturbance of the sleep-wake cycle is a characteristic of delirium. In addition, changes in melatonin rhythm influence the circadian rhythm and are associated with delirium. We compared the effect of melatonin and placebo on the incidence and duration of delirium. METHODS: We performed this multicentre, double-blind, randomized controlled trial between November 2008 and May 2012 in 1 academic and 2 nonacademic hospitals. Patients aged 65 years or older who were scheduled for acute hip surgery were eligible for inclusion. Patients received melatonin 3 mg or placebo in the evening for 5 consecutive days, starting within 24 hours after admission. The primary outcome was incidence of delirium within 8 days of admission. We also monitored the duration of delirium. RESULTS: A total of 452 patients were randomly assigned to the 2 study groups. We subsequently excluded 74 patients for whom the primary end point could not be measured or who had delirium before the second day of the study. After these postrandomization exclusions, data for 378 patients were included in the main analysis. The overall mean age was 84 years, 238 (63.0%) of the patients lived at home before admission, and 210 (55.6%) had cognitive impairment. We observed no effect of melatonin on the incidence of delirium: 55/186 (29.6%) in the melatonin group v. 49/192 (25.5%) in the placebo group; difference 4.1 (95% confidence interval -0.05 to 13.1) percentage points. There were no between-group differences in mortality or in cognitive or functional outcomes at 3-month follow-up. INTERPRETATION: In this older population with hip fracture, treatment with melatonin did not reduce the incidence of delirium. TRIAL REGISTRATION: Netherlands Trial Registry, NTR1576: MAPLE (Melatonin Against PLacebo in Elderly patients) study; www.trialregister.nl/trialreg/admin/rctview.asp?TC=1576.
Authors: M S Albert; S E Levkoff; C Reilly; B Liptzin; D Pilgrim; P D Cleary; D Evans; J W Rowe Journal: J Geriatr Psychiatry Neurol Date: 1992 Jan-Mar Impact factor: 2.680
Authors: Barbara C van Munster; Johanna C Korevaar; Aeilko H Zwinderman; Marcel Levi; W Joost Wiersinga; Sophia E De Rooij Journal: J Am Geriatr Soc Date: 2008-08-04 Impact factor: 5.562
Authors: Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman Journal: J Clin Psychiatry Date: 2003-02 Impact factor: 4.384
Authors: Tianjing Li; L Susan Wieland; Esther Oh; Karin J Neufeld; Nae-Yuh Wang; Kay Dickersin; Frederick E Sieber Journal: Clin Trials Date: 2017-01-09 Impact factor: 2.486
Authors: Christopher G Hughes; Christina S Boncyk; Deborah J Culley; Lee A Fleisher; Jacqueline M Leung; David L McDonagh; Tong J Gan; Matthew D McEvoy; Timothy E Miller Journal: Anesth Analg Date: 2020-06 Impact factor: 5.108
Authors: Stuti J Jaiswal; Thomas J McCarthy; Nathan E Wineinger; Dae Y Kang; Janet Song; Solana Garcia; Christoffel J van Niekerk; Cathy Y Lu; Melissa Loeks; Robert L Owens Journal: Am J Med Date: 2018-05-03 Impact factor: 4.965
Authors: Esther S Oh; Jeannie-Marie Leoutsakos; Paul B Rosenberg; Alexandra M Pletnikova; Harpal S Khanuja; Robert S Sterling; Julius K Oni; Frederick E Sieber; Neal S Fedarko; Narjes Akhlaghi; Karin J Neufeld Journal: Am J Geriatr Psychiatry Date: 2020-05-16 Impact factor: 4.105